ImmunityBio公司Anktiva针对BCG初治NMIBC患者的随机试验入组进度超前 预计2026年第二季度完成全部入组

美股速递
Jan 14

ImmunityBio公司宣布,其针对BCG初治型非肌层浸润性膀胱癌患者开展的Anktiva随机试验,目前患者入组进度较原计划大幅超前。根据最新时间表,这项重要临床研究预计将于2026年第二季度完成全部患者招募工作。

该试验旨在评估Anktiva在BCG未接受过的NMIBC患者群体中的疗效与安全性。研究进度的加速推进,为早日获得关键临床数据奠定了坚实基础,也反映出医疗界对该创新疗法的积极参与和高度期待。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10